Clinical Trials Browser

Mycosis Fungoides, Sezary Syndrome

NCT05010005 2026-04-09

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Phase 1 Recruiting

70 enrolled

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Leukemia, Large Granular Lymphocytic

NCT07001384 2026-04-08

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Phase 1 Recruiting

30 enrolled

Lymphoid

Lymphoma, Large-Cell, Anaplastic

NCT06522737 2026-04-06

TERZO

Phase 3 Recruiting

124 enrolled

Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Lymphoma, T-Cell, Peripheral

NCT04803201 2026-04-02

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Phase 2 Suspended

170 enrolled

Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT03534323 2026-03-23

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

Phase 1/2 Active not recruiting

55 enrolled 14 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02158091 2026-02-13

A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

Phase 1/2 Active not recruiting

32 enrolled 11 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05044039 2026-02-02

Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

Phase 1 Active not recruiting

42 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03961672 2026-01-05

Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2 Active not recruiting

15 enrolled 13 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04331119 2025-12-30

Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

Phase 2 Active not recruiting

17 enrolled

Lymphoid

Lymphoma, T-Cell

NCT07293403 2025-12-19

Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas

Phase 2 Not yet recruiting

25 enrolled

Lymphoid

Lymphoma, T-Cell

NCT05065866 2025-12-04

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Phase 1 Completed

14 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Neoplasms, Plasma Cell

NCT05057247 2025-10-31

Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

Phase 2 Completed

26 enrolled 23 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06810778 2025-07-15

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Phase 1/2 Recruiting

12 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Leukemia, Prolymphocytic, T-Cell

NCT02783625 2025-06-03

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

Phase 1 Active not recruiting

114 enrolled

Lymphoid

Lymphoma, Lymphoma, T-Cell

Clinical Trials

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

TERZO

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas